Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Total Debt?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Total Debt is 
$10.2B (1Y +0.45% )

ALXN Stock Price & Total Debt

Total Debt for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Total Debt

chevron_right 2021 $2.6B +3201x
( +34.8% / year avg)
chevron_left 1995 $800.0K
vertical_align_top Peak $12.0B +17097x
vertical_align_bottom Bottom $700.0K
arrow_drop_up # Up Years 15 15 of 27
years up.
arrow_drop_down # Down Years 12
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.01x the rate relative to it's total debt over the same period.
  • If ALXN grows it's stock at the same rate as it's total debt (+34.8%/year) , it's stock price will grow +1,981% and hit $2153.81 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 15 years (0%) it's total debt were also up.
  • ALXN Historical Total Debt Table
    in $ million
    Year Total Debt YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $2,562 -74.4% - -
    4/1/2020 $10,002 -5.1% - -
    4/1/2019 $10,540 -7.7% - -
    4/1/2018 $11,422 -4.6% - -
    4/1/2017 $11,969 20.2% - -
    4/1/2016 $9,954 37.9% - -
    4/1/2015 $7,217 1919.0% - -
    4/1/2014 $357 -36.2% - -
    4/1/2013 $560 -24.9% - -
    4/1/2012 $745 876.1% - -
    4/1/2011 $76 33.4% - -
    4/1/2010 $57 -84.6% - -
    4/1/2009 $371 -54.8% - -
    4/1/2008 $821 13.6% - -
    4/1/2007 $722 20.4% - -
    4/1/2006 $600 -16.7% - -
    4/1/2005 $720 47.7% - -
    4/1/2004 $487 -2.9% - -
    4/1/2003 $502 1.3% - -
    4/1/2002 $495 -0.1% - -
    4/1/2001 $495 31.4% - -
    4/1/2000 $377 2351.7% - -
    4/1/1999 $15 396.8% - -
    4/1/1998 $3 342.9% - -
    4/1/1997 $0 -66.7% - -
    4/1/1996 $2 162.5% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Total (gross) debt is the total amount of debt a company has at a certain point in time

    For more detailed definitions, please see Investopedia.